Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-12
2005-04-12
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S381000
Reexamination Certificate
active
06878703
ABSTRACT:
A pharmaceutical composition comprises an angiotensin II receptor antagonist selected from among compounds having the following formula (I), a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof and a pharmacologically acceptable salt of such ester, and one or more diuretics:The pharmaceutical composition of the present invention has an excellent hypotensive effect and low toxicity, and therefore is useful as a medicament for preventing or treating hypertension or heart disease.
REFERENCES:
patent: 2554816 (1951-05-01), Clapp et al.
patent: 2783241 (1957-02-01), Young et al.
patent: 2835702 (1958-05-01), Schultz
patent: 2976289 (1961-03-01), Cohen et al.
patent: 2980679 (1961-04-01), Pala
patent: 3009911 (1961-11-01), McManus
patent: 3025292 (1962-03-01), Jones et al.
patent: 3055904 (1962-09-01), Graf et al.
patent: 3058882 (1962-10-01), Stürm et al.
patent: 3108097 (1963-10-01), Ugi
patent: 3163645 (1964-12-01), de Stevens et al.
patent: 3183243 (1965-05-01), Lee et al.
patent: 3254076 (1966-05-01), Lund et al.
patent: 3255241 (1966-06-01), Schultz et al.
patent: 3265573 (1966-08-01), Goldberg
patent: 3313813 (1967-04-01), Cragoe, Jr.
patent: 3356692 (1967-12-01), Horstmann et al.
patent: 3360518 (1967-12-01), Shetty
patent: 3567777 (1971-03-01), Liebenow
patent: 3634583 (1972-01-01), Feit
patent: 3758506 (1973-09-01), Godfroid et al.
patent: 5138069 (1992-08-01), Carini et al.
patent: 5153197 (1992-10-01), Carini et al.
patent: 5264447 (1993-11-01), Ohtawa
patent: 5310928 (1994-05-01), Lo et al.
patent: 5616599 (1997-04-01), Yanagisawa et al.
patent: 5656650 (1997-08-01), Weinstock
patent: 639386 (1963-10-01), None
patent: 0 400 835 (1990-12-01), None
patent: 0 503 785 (1992-09-01), None
patent: 0 733 366 (1996-09-01), None
patent: 795174 (1958-05-01), None
patent: 851287 (1960-10-01), None
patent: WO 8906233 (1989-07-01), None
Krousel-Wood et al., “Primary Prevention of Essential Hypertension”, Med. Clncs. of North Am., (Jan. 2004) 88(1) 223-38. (Abstract only).*
C.W. Whitehead et al., Diuretics, V, 3,4-Dihydro-1,2,4-benzothiadiazine 1,1-Dioxides,J. Org. Chem., 26,(1961), pp. 2814-2818.
Stevens et al.,Experientia,“The Chemistry and Pharmacology of Hydrotrichlorothiazide”, 16, (1960), p. 113-114.
Close et al., “Synthesis of Potential Diuretic Agents. I. Derivatives of 7-Sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-Dioxide”,J. Am. Chem. Soc., 82,(1960), pp. 1132-1135.
Jucker et al., “Ūber diuretisch wirksame Benzoesäure-Derivate”,Helv. Chim. Acta., 45,(1962), pp. 2316-2325.
Satoh et al., “Enhancement of the Hypotensive Effect of Hydralazine by a New Sulfamoylbenzamide Type Diuretic-hypotensive Agentin DOCA-hypertensive Rats”,Oyo Yakuri, 21(1981), pp. 607-611.
Davies et al., “The Comparative Effects of the Nitro-, Carboxyl, and Sulphonic Acid Groups on the Hydrolysis of Aryl Halides”,J. Chem. Soc.,(1928), pp. 1122-1131.
E. Jucker and A. Lindenmann, “Diuretic Activities of Benzoic Acid Derivatives”,Helv. Chim. Acta.,45 (1962), pp. 2316-2325.
Graul, A. et al., “CS-866: Antihypertensive Angiotensin II Antagonist”,Drugs of the Future,vol. 22, No. 11, Nov. 1997, pp. 1205-1209.
Danser, A.J. et al. “18th Scientific Meeting of the International Society of Hypertension”,Expert Opinion on Investigational Drugs,Ashley Publications Ltd., London, GB, vol. 9, No. 10, Aug. 20, 2000, pp. 2419-2423.
Critchley, Julian A.J.H. et al., “A Randomized, Double-Masked Comparison of the Antihypertensive Efficacy and Safety of Combination Therapy with Losartan and Hydrochlorothiazide Versus Captopril and Hydrochlorothiazide in Elderly and Younger Patients”,Current Therapeutic Research,vol. 57, No. 5, 1996, pp. 392-407.
Koike, H., et al., “In vitro and In vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1receptor antagonist”,Journal of Hypertension,vol. 19 (Suppl. 1) pp. S3-S14, Jun. 2001.
Brunner, Hans R., “Olmesartan medoxomil: a new AT1receptor antagonist for the treatment of hypertension”,Journal of Hypertension,vol. 19 ((Suppl. 1) S1-S2, Jun. 2001.
Brunner, Hans R., “Relevance of clinical pharmacological models for the evaluation of threapeutic dose range of an AT1-receptor antagonist”,Journal of Hypertension,vol. 19 (Suppl. 1) S15-S20, Jun. 2001.
Laeis, Petra, et al., “The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction”,Journal of Hypertension,vol. 19 (Suppl. 1) S21-S48, Jun. 2001.
Von Bergmann, Klaus, et al., “Olmesartan moedoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil”,Journal of Hypertension,vol. 19 (Suppl. 1), S33-S40, Jun. 2001.
Püchler, Kurt, et al., “Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist”,Journal of Hypertension,vol. 19 (Suppl. 1), S41-S48, Jun. 2001.
Fliser, Danilo, et al., “Angiotensin II subtype 1-receptor antagonists in the treatment of diabetic nephropathy”,Journal of Hypertension,vol. 19 (Suppl. 1) S57-S60, Jun. 2001.
McInnes, Gordon T., “Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antageonist?”,Journal of Hypertension,vol. 19 (Suppl. 1) S61-S67, Jun. 2001.
Ball, Keith J., “Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives”,Journal of Hypertension,vol. 19 (Suppl. 1) S49-S56, Jun. 2001.
Mizuno Makoto
Sada Toshio
Frishauf Holtz Goodman & Chick P.C.
Henley III Raymond J.
Sankyo Company Limited
LandOfFree
Pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3386150